companydata.dkcompanydata.dk

Afyx Therapeutics A/S: Financial statements 2024

CVR: 38793594

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 23,467,830 and a net result of DKK -3,810,585 compared with DKK -2,253,249 the year before. That is an increase of 266.4% compared with the year before. Equity in the 2024 report amounted to DKK 9,660,111. The solvency ratio was 62.5%. The company had 11 employees in the financial year.

Gross Profit
DKK 23,467,830
Profit/Loss
DKK -3,810,585
Equity
DKK 9,660,111
Total Assets
DKK 15,462,845
Employees
11

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-23.5M-3.8M9.7M11
2023-6.4M-2.3M4.7M5
2022--3.2M-7.3M-1M3
2021-1.5M-814K6.2M2
2020--586K-1.5M4.7M2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Afyx Therapeutics A/S appoints new auditorDec 3, 2024

As of December 3, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Afyx Therapeutics A/S.

Auditor steps down at Afyx Therapeutics A/SDec 3, 2024

As of December 3, 2024, GILFELT REVISION REGISTRERET REVISIONSANPARTSSELSKAB has stepped down as auditor of Afyx Therapeutics A/S.

Afyx Capital ApS registered as owner of Afyx Therapeutics A/SJun 18, 2024

As of June 18, 2024, Afyx Capital ApS is registered as an owner of Afyx Therapeutics A/S with an ownership share of 66%.

Afyx Therapeutics A/S: The 2023 annual report is outApr 16, 2024

Afyx Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 6,404,980, and the net result was DKK -2,253,249.

Søren Mohrsen Kjær joins the board of Afyx Therapeutics A/SApr 3, 2024

As of April 3, 2024, Søren Mohrsen Kjær has joined the board of directors of Afyx Therapeutics A/S.

Inphena A/S changes name to Afyx Therapeutics A/SApr 3, 2024

On April 3, 2024, the company changed its name from Inphena A/S to Afyx Therapeutics A/S.

About Afyx Therapeutics A/S

Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.

Source: annual report 2025, Danish Business Authority

Other financial years